Entera Bio
ENTX
5 hedge funds and large institutions have $2.01M invested in Entera Bio in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.26% less ownership
Funds ownership: 10.45% → 10.19% (-0.26%)
15% less capital invested
Capital invested by funds: $2.36M → $2.01M (-$355K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$79.8K |
| 2 |
VF
Virtu Financial
New York
|
+$34.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$151K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.14K |
ENTX Hedge Fund Activity: Q4 2020 in Review
5 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2020, worth a combined $2.01M — down 15% from $2.36M a quarter earlier.
Fund positioning in ENTX was balanced in Q4 2020: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $79.8K. The largest seller was Wedbush Securities, exiting entirely with an estimated $151K sold.
- 5 institutional investors held Entera Bio (ENTX) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $2.01M of Entera Bio stock for Q4 2020, down 15% quarter-over-quarter.
- 2 funds opened new Entera Bio positions in Q4 2020 and 2 closed out, a net change of 0 holders.
- The largest Entera Bio buyer in Q4 2020 was Renaissance Technologies, an estimated $79.8K added.
- The largest Entera Bio seller in Q4 2020 was Wedbush Securities, an estimated $151K sold.
Based on aggregated 13F filings for Q4 2020.